Results 131 to 140 of about 86,158 (258)

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff   +3 more
wiley   +1 more source

Suggestive causal associations between 17 autoimmune diseases and pancreatitis: A two-sample Mendelian randomization study. [PDF]

open access: yesMedicine (Baltimore)
Huang D   +13 more
europepmc   +1 more source

Clinical Significance of a Cell‐Of‐Origin‐Based Classification in Pancreatic Ductal Adenocarcinoma

open access: yesCancer Science, EarlyView.
Schematic overview of a cell‐of‐origin‐based classification of pancreatic ductal adenocarcinoma (PDAC), highlighting distinct biological features and therapeutic implications of Acinar‐ and Ductal‐subtypes. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor clinical ...
Tatsuya Kikuchi   +21 more
wiley   +1 more source

User satisfaction with fingerstick versus continuous glucose monitoring in surgical wards: A two‐centre non‐randomised clinical trial

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims To compare person‐reported outcomes on point‐of‐care (POC) fingerstick glucose monitoring (FSGM) with POC continuous glucose monitoring systems (CGMS) in adults admitted to surgical wards. The primary outcome was convenience; the secondary outcome was satisfaction with diabetes‐related treatment.
Tine Lumbye Thomsen   +6 more
wiley   +1 more source

Real‐world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

open access: yesDiabetic Medicine, EarlyView.
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy